Evidence map›Paper›PMID 29771928›Full record

ArticlePloS one2018

ChIP-exo interrogation of Crp, DNA, and RNAP holoenzyme interactions.

Haythem Latif, Stephen Federowicz, Ali Ebrahim, Janna Tarasova, Richard Szubin, Jose Utrilla, Karsten Zengler, Bernhard O Palsson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. A systems-level atlas of carbon-response transcriptional states inProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. ChEAP: ChIP-exo analysis pipeline and the investigation ofComputational and structural biotechnology journal · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Haythem LatifBioengineering Department, University of California San Diego, La Jolla, California, United States of America.
Stephen FederowiczBioengineering Department, University of California San Diego, La Jolla, California, United States of America.
Ali EbrahimBioengineering Department, University of California San Diego, La Jolla, California, United States of America.
Janna TarasovaBioengineering Department, University of California San Diego, La Jolla, California, United States of America.
Richard SzubinBioengineering Department, University of California San Diego, La Jolla, California, United States of America.
Jose UtrillaBioengineering Department, University of California San Diego, La Jolla, California, United States of America.
Karsten ZenglerBioengineering Department, University of California San Diego, La Jolla, California, United States of America.
Bernhard O PalssonBioengineering Department, University of California San Diego, La Jolla, California, United States of America.ORCID 0000-0003-2357-6785
University of California San Diego · USNovo Nordisk Foundation · DK

Funding

GENOMICALLY BASED MODELS FOR ANTIBIOTIC DEVELOPMENTR01GM057089 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PALSSON, BERNHARD O · 1998 to 2021
$6.9M
Multiscale Molecular Systems Biology: Reconstruction and Model OptimizationU01GM102098 · NIGMS · STANFORD UNIVERSITY · PI SAUNDERS, MICHAEL ALAN · 2012 to 2016
$1.8M
NIGMS NIH HHS R01 GM057089NIGMS NIH HHS U01 GM102098
6 · The paper itself

Abstract

Numerous in vitro studies have yielded a refined picture of the structural and molecular associations between Cyclic-AMP receptor protein (Crp), the DNA motif, and RNA polymerase (RNAP) holoenzyme. In this study, high-resolution ChIP-exonuclease (ChIP-exo) was applied to study Crp binding in vivo and at genome-scale. Surprisingly, Crp was found to provide little to no protection of the DNA motif under activating conditions. Instead, Crp demonstrated binding patterns that closely resembled those generated by σ70. The binding patterns of both Crp and σ70 are indicative of RNAP holoenzyme DNA footprinting profiles associated with stages during transcription initiation that occur post-recruitment. This is marked by a pronounced advancement of the template strand footprint profile to the +20 position relative to the transcription start site and a multimodal distribution on the nontemplate strand. This trend was also observed in the familial transcription factor, Fnr, but full protection of the motif was seen in the repressor ArcA. Given the time-scale of ChIP studies and that the rate-limiting step in transcription initiation is typically post recruitment, we propose a hypothesis where Crp is absent from the DNA motif but remains associated with RNAP holoenzyme post-recruitment during transcription initiation. The release of Crp from the DNA motif may be a result of energetic changes that occur as RNAP holoenzyme traverses the various stable intermediates towards elongation complex formation.

Indexed as

Bacterial Outer Membrane ProteinsChromatin ImmunoprecipitationCyclic AMP Receptor ProteinDNA, BacterialDNA-Directed RNA PolymerasesDNA FootprintingEscherichia coliEscherichia coli ProteinsGene ExpressionHoloenzymesIron-Sulfur ProteinsMutationProtein BindingRepressor ProteinsTranscription, GeneticarcA protein, E coliBacterial Outer Membrane Proteinscrp protein, E coliCyclic AMP Receptor ProteinDNA, BacterialDNA-Directed RNA PolymerasesEscherichia coli ProteinsFNR protein, E coliHoloenzymesIron-Sulfur ProteinsRepressor Proteins

Identifiers

PMID29771928
PMCPMC5957442
OpenAlexW2951764736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.